Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Abstract Introduction Long-term (1-year) fremanezumab treatment proved to be effective, safe, and well tolerated in individuals with migraine and < 2 medication clusters in a randomized controlled trial (RCT). We aimed to assess real-world evidence (RWE), long-term effectiveness, tolerability, and s...

Полное описание

Библиографические подробности

Главные авторы:	Piero Barbanti, Gabriella Egeo, Stefania Proietti, Florindo d’Onofrio, Cinzia Aurilia, Cinzia Finocchi, Laura Di Clemente, Maurizio Zucco, Alberto Doretti, Stefano Messina, Massimo Autunno, Angelo Ranieri, Antonio Carnevale, Bruno Colombo, Massimo Filippi, Miriam Tasillo, Steno Rinalduzzi, Pietro Querzani, Giuliano Sette, Lorenzo Forino, Francesco Zoroddu, Micaela Robotti, Alessandro Valenza, Cecilia Camarda, Laura Borrello, Marco Aguggia, Giovanna Viticchi, Carlo Tomino, Giulia Fiorentini, Bianca Orlando, Stefano Bonassi, Paola Torelli, for the Italian Migraine Registry study group
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Adis, Springer Healthcare 2024-03-01
Серии:	Neurology and Therapy
Предметы:	Fremanezumab Migraine treatment CGRP monoclonal antibody Real-world Long-term treatment Psychiatric comorbidities
Online-ссылка:	https://doi.org/10.1007/s40120-024-00591-z
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!